Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: can + improve + tumor  Related to the article below (Last Update: 8/5/2008)

For the men who develop prostate cancer, early testing can improve ...
Orlando Sentinel, FL -
... to monitor the possible growth of the tumor, American doctors -- and patients -- usually don't choose that option unless the patient is 75 or older. ...
Stop prostate exams at age 75, federal panel recommends
Los Angeles Times, CA -
High blood levels of the antigen in the test generally indicate the presence of a tumor. But confirming it requires a biopsy. Current guidelines from the ...
Ansgerius Takalapeta: Regent proves his green spirit
Jakarta Post, Indonesia -
He was able to convince the community to raise rusa Tumor (Tumor deer, Cervus timorensis) in an area where people normally raised livestock such as pigs and ...
OxiGene, Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha, NY -
... one of the largest markets within the oncology field and there is a high unmet need for new drugs that can improve patient?s survival and outcome. ...OXGN
When health problems are skin deep
Chester DailyLocal.com,  USA - Aug 4, 2008
There are other medications that can be taken," said Kuffner. "Sometimes sunlight and water can improve symptoms." Treatment varies depending upon each ...
Health Front and Center
Publishers Weekly, NY -
Author David Servan Schreiber, a founding member of Doctors Without Borders, was diagnosed with a brain tumor at 31. Editor-at-large Carole DeSanti says, ...

The Star-Ledger - NJ.com
Keeping Katie Reider's voice alive
The Star-Ledger - NJ.com, NJ -
As summer began, Reider's condition seemed to improve. Doctors told her the tumor was more than 95 percent gone. But while on vacation in Delaware, ...
One Fifth Of British Adult Survivors Of Childhood Cancer Smoke ...
Science Daily (press release) -
When the researchers analyzed the responses by tumor site, they found that survivors of central nervous system cancers or heritable retinoblastoma were ...
Behavioral Comorbidities in Rheumatoid Arthritis
Psychiatric Times, NY -
We also describe behavioral treatment strategies that can improve the clinical management of these patients. A broad range of illnesses has been associated ...
Adding PAND to Radical Gastrectomy Does Not Improve Survival in ...
Abkhazia, CA - Jul 31, 2008
The hazard ratio for death was 1.03, and after adjustment for standard variables, including age, sex, body mass index, tumor location, tumor size, ...
Source: Google News

… Carcinoma: Can Double Arterial Phase Imaging with Multidetector CT Improve Tumor Depiction in the … -
T Ichikawa, T Kitamura, H Nakajima, H Sou, T … - American Journal of Roentgenology, 2002 - Am Roentgen Ray Soc
... Hypervascular Hepatocellular Carcinoma: Can Double Arterial Phase Imaging with
Multidetector CT Improve Tumor Depiction in the Cirrhotic Liver? ...

Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart A New Era in … -
EJ Eichhorn, MR Bristow - Circulation, 1996 - Am Heart Assoc
... 86 Additionally, the cytokine tumor necrosis factor- (TNF- ), which is increased ...
Evidence That Medical Therapy Can Improve the Inherent Biological Function of ...

… can be induced to present alloantigen efficiently: a conceptual model to improve their tumor … -
JL Schultze, AA Cardoso, GJ Freeman, MJ Seamon, J … - Proceedings of the National Academy of Sciences of the …, 1995 - pubmedcentral.nih.gov
... Copyright notice. Follicular lymphomas can be induced to present alloantigen
efficiently: a conceptual model to improve their tumor immunogenicity. ...

Oral administration of psk can improve the impaired anti-tumor CD 4 T-cell response in gut- … -
M Harada, K Matsunaga, Y Oguchi, H Iijima, K … - International Journal of Cancer, 1997 - doi.wiley.com
ORAL ADMINISTRATION OF PSK CAN IMPROVE THE IMPAIRED ANTI-TUMOR CD4 1 T-CELL RESPONSE
IN GUT-ASSOCIATED LYMPHOID TISSUE (GALT) OF SPECIFIC-PATHOGEN-FREE MICE ...

Can erythropoietin improve tumor oxygenation? -
DK Kelleher, O Thews, P Vaupel - Strahlenther Onkol, 1998 - ncbi.nlm.nih.gov
... These findings suggested that rhEPO treatment can improve tumor oxygenation
by increasing the O2 availability to tumor tissue. Further ...

… screening. The use of serial complementary tumor markers to improve sensitivity and specificity for … -
JS Berek, RC Bast Jr - Cancer, 1995 - ncbi.nlm.nih.gov
... The use of serum tumor markers for the early detection of ovarian cancer ... The serial
measurement of complementary serum markers can improve the use of marker ...

Psychological Science Can Improve Diagnostic Decisions -
JA Swets, RM Dawes, J Monahan - Psychological Science in the Public Interest, 2000 - Blackwell Synergy
... be presented in detail to illustrate improve- ments in ... improvements in decision utility
that can stem from ... such features include (a) a ?mass? (tumor or a ...

Role of the p16 tumor suppressor gene in cancer -
WH Liggett Jr, D Sidransky - Journal of Clinical Oncology, 1998 - jco.ascopubs.org
... in carcinogenesis, rivaled in frequency only by the p53 tumor-suppressor gene. ... and
perhaps lead to better therapeutic strategies that can improve the clinical ...

… and characterization of a complementary DNA (galanin) clone from estrogen-induced pituitary tumor … -
ME Vrontakis, LM Peden, ML Duckworth, HG Friesen - Journal of Biological Chemistry, 1987 - ASBMB
... Sulfate, and Dithiothreitol in the Hybridization Buffer Can Improve Results of In ...
and Hyperplastic Anterior Pituitary Cells: From Pituitary Tumor Cell Lines to ...

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells -
CA Klebanoff, SE Finkelstein, DR Surman, MK … - Proceedings of the National Academy of Sciences, 2004 - National Acad Sciences
... By removing endogenous IL-15 by using tumor-bearing IL-15 knockout hosts or ... by
adoptively transferred T cells, we demonstrate that IL-15 can improve the in ...

Source: Google Scholar

Temporary Improvement Of Tumor Blood Flow Can Improve Chemotherapy
A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one, according to results of studies at St. Jude Children's Research Hospital. Neuroblastoma is a pediatric solid tumor that arises from cells in the peripheral nervous system.

The finding holds promise for improving neuroblastoma treatment by using the drug bevacizumab to block VEGF, a protein that stimulates blood vessel growth in tumors and then following with the chemotherapy drug topotecan, which depends on blood vessels to penetrate the tumor and kill the cancer cells. A report on this work appears in the current issue of Clinical Cancer Research.
Results of the current study are especially important because drugs such as bevacizumab are being evaluated in clinical trials for children with neuroblastoma. However, there are no standard guidelines for how much of the drug to give or when to give it. Such guidelines would be especially helpful for developing combination therapy with both bevacizumab and chemotherapy drugs, not only for neuroblastoma, but also for other tumors.

"The results of our study are a significant step toward establishing such guidelines," said Andrew Davidoff, M.D., director of surgical research at St. Jude, and the report's senior author.

The St. Jude team based their strategy on previous findings that suggested blocking VEGF at first improves the tumor's vasculature, or blood vessel system, by eliminating weak and faulty vessels, while temporarily sparing healthy, normal blood vessels. The investigators reasoned that if they treated tumors with bevacizumab first, the temporarily improved tumor circulation would more efficiently deliver topotecan but only if they timed this one-two punch correctly.

"A growing tumor releases VEGF to stimulate growth of the blood vessels that support its own growth," Davidoff said. "But much of this new vasculature is poorly constructed and leaks fluid into the spaces around the cancerous cells, increasing the pressure inside the tumor. This increased pressure outside the vasculature acts like a wall to prevent cancer drugs from passing through the blood vessels."

Bevacizumab eliminates the shoddy vasculature, temporarily sparing the more sturdily built vessels, which do not leak fluid, but deliver the drug throughout the tumor, Davidoff said.

Davidoff's team first treated mouse models that carried transplanted human neuroblastomas with a single dose of bevacizumab. They studied the changes in the tumor vasculature at different times after treatment with a single dose of bevacizumab; finally, they studied how well topotecan penetrated the tumor and inhibited its growth when given at different intervals after bevacizumab.
The researchers showed that bevacizumab reduced the density of the tumor's vasculature to less than 30 percent of that in untreated tumors within seven days, accompanied by a significant decrease in pressure in the tumor caused by fluid passing through from the blood vessels. The remaining, normalized vasculature perfused the tumor more thoroughly than before treatment with bevacizumab; and the amount of topotecan it carried throughout the tumor was about 80 percent more when given one to three days after bevacizumab compared to when both drugs were given either at the same time or seven days apart.

When the researchers administered topotecan to the tumor-bearing mice three days after bevacizumab, the size of the tumors was only 36 percent of the size of untreated tumors, compared to 88 percent when mice were treated with bevacizumab alone; 54 percent when treated with topotecan alone; and 44 percent when tumor-bearing mice were treated with both drugs at the same time.

"We observed in the mouse model of neuroblastoma that the maximum amount of topotecan reached the tumor and had maximum tumor-reducing effect if we waited three days after administering bevacizumab," Davidoff said. "This suggested that combination treatment of children with neuroblastoma should take into account that there is a window of opportunity for improving topotecan delivery after treatment with bevacizumab. Further studies should tell us how long that window is open."

Other authors of the study include Paxton Dickson, John Hamner, Thomas Sims, Charles Fraga, Catherine Ng, Surender Rajasekeran, Nikolaus Hagedorn, M. Beth McCarville and Clinton Stewart.

This work was supported in part by the Alliance for Cancer Gene Therapy, the Assisi Foundation of Memphis, the U.S. Public Health Service Childhood Solid Tumor Program, a Cancer Center Support Grant from the National Cancer Institute and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit http://www.stjude.org.

St. Jude Children's Research Hospital
332 N. Lauderdale St., Mail Stop 761
Memphis, TN 38122
United States
http://www.stjude.org
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.